Scilex Holding Co. (SCLX)

$5.30 -0.08 (-1.49%)
Market Cap 37.40M
Revenue (ttm) 56.59M
Net Income (ttm) -72.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -128.66%
Debt to Equity Ratio -0.19
Volume 47,300
Avg Vol 161,170
Day's Range N/A - N/A
Shares Out 6.95M
Stochastic %K 72%
Beta 1.13
Analysts Strong Buy
Price Target $367.13

Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 516 4310
Address:
960 San Antonio Road, Palo Alto, United States
nelly2k
nelly2k Jun. 27 at 4:17 AM
$SRNE $SCLX who is still holding SRNE .. any longs or shorts still here? or we all retired and living on the beach.
0 · Reply
Tight_grapes
Tight_grapes Jun. 27 at 3:58 AM
$SCLX $SRNE Can a bull explain how this company can remain solvent? This could file for BK any day at this point. Exiting 2025 intact seems close to impossible barring some sort of major asset sale or miraculous rabbit puled out of hat w/ the FDA. They have no trajectory to make money, or even close that I can see, they cannot dilute much more, and the SPAC has not consummated in close to 12 months after annoucement... This looks very much like Sorrento 2.0 and no matter how much Ji "wants" to help, a failing company is a failing company which try as he might, is still failing... Anyone?
1 · Reply
JustAGoodOleBoy22
JustAGoodOleBoy22 Jun. 27 at 3:50 AM
$SCLX Question...hypothetically if Hji and Shah went on shark tank...could they convince anyone to invest in this shit
0 · Reply
JustAGoodOleBoy22
JustAGoodOleBoy22 Jun. 27 at 3:46 AM
$SCLX $37 million Market Cap....how much does the BOD and Ceo make again?
0 · Reply
JustAGoodOleBoy22
JustAGoodOleBoy22 Jun. 27 at 12:10 AM
$SCLX So Hji Jr...the former tennis star...Mba at Woke ColumbiaU (paid for by us) ...works for Moelis...? huh
0 · Reply
Rookie69
Rookie69 Jun. 26 at 7:18 PM
$SCLX Shareholders can only pray that this next phase 3 is kicked back by the FDA too. How awesome would it be to run more trials and gather even that much more efficacy dats
1 · Reply
SCLXSUX
SCLXSUX Jun. 26 at 6:07 PM
$SCLX - Ji set the price target!!!! I think he's probably close on his projection. It should bring in the remaining gullible looking for the "easy money". You might as well build a fire with your money and roast some weenies, because you won't have any money left after you invest in this steaming pile of...
1 · Reply
qlox
qlox Jun. 26 at 5:39 PM
$SCLX A price target of $367.50 ??? Are you out of your freaking mind!?
1 · Reply
Tight_grapes
Tight_grapes Jun. 26 at 4:55 PM
$SCLX $SRNE I would bet that the professionals Ji hired at Lantham, M3, and Moelis were not aware at the bankruptcy filing that Scilex was worthless...that the ZTlido patent was junk, Semdexa failed in its Phase 3 design, etc. That truth likely was uncovered during the tortuous BK process and the entire bankruptcy went FUBAR as a result... Lol. But the pumpers attacked the professionals and the courts...not Ji. Ji screwing up is the ESSENCE, the DNA, the foundation of ALL his business dealings. How he can do so, and do so HUGELY, while self-enriching is nothing short of phenomenal. He is the Stephen Curry enrichment by failure. A true legend.
1 · Reply
Jigoingtoprison
Jigoingtoprison Jun. 26 at 4:38 PM
$SCLX this will follow suit with #srne … I’ve been involved in JI company’s for 7 years. Biggest mistake of my life.
1 · Reply
Latest News on SCLX
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

Jun 23, 2025, 4:50 PM EDT - 3 days ago

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

Jun 5, 2025, 12:05 PM EDT - 21 days ago

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025, 9:00 AM EDT - 5 weeks ago

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025, 9:00 AM EDT - 2 months ago

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Apr 30, 2025, 1:46 PM EDT - 2 months ago

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Apr 22, 2025, 9:00 AM EDT - 2 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Apr 16, 2025, 2:12 PM EDT - 2 months ago

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Apr 15, 2025, 9:00 AM EDT - 2 months ago

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Apr 11, 2025, 9:00 AM EDT - 2 months ago

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Mar 26, 2025, 8:24 PM EDT - 3 months ago

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Mar 10, 2025, 9:00 AM EDT - 3 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Jan 31, 2025, 9:00 AM EST - 5 months ago

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Jan 21, 2025, 11:49 AM EST - 5 months ago

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Jan 21, 2025, 9:46 AM EST - 5 months ago

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Jan 21, 2025, 9:00 AM EST - 5 months ago

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Jan 21, 2025, 6:00 AM EST - 5 months ago

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Jan 16, 2025, 3:38 PM EST - 5 months ago

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Dec 30, 2024, 9:00 AM EST - 6 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Dec 13, 2024, 12:23 PM EST - 6 months ago

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Scilex Holding Company Announces $17 Million Registered Direct Offering

Dec 12, 2024, 8:21 AM EST - 7 months ago

Scilex Holding Company Announces $17 Million Registered Direct Offering

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Dec 11, 2024, 12:49 PM EST - 7 months ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Dec 11, 2024, 7:30 AM EST - 7 months ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Nov 22, 2024, 6:00 AM EST - 7 months ago

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Nov 6, 2024, 12:24 PM EST - 8 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Oct 30, 2024, 6:00 AM EDT - 8 months ago

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Oct 29, 2024, 6:00 AM EDT - 8 months ago

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Oct 28, 2024, 6:00 AM EDT - 8 months ago

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Oct 16, 2024, 4:00 AM EDT - 9 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

Oct 8, 2024, 1:58 PM EDT - 9 months ago

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

Oct 8, 2024, 11:50 AM EDT - 9 months ago

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oct 7, 2024, 10:00 AM EDT - 9 months ago

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

ORMP

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

Oct 7, 2024, 9:52 AM EDT - 9 months ago

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

Top 3 Health Care Stocks That Could Blast Off In September

Sep 10, 2024, 7:27 AM EDT - 10 months ago

Top 3 Health Care Stocks That Could Blast Off In September

AMN PDCO

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Sep 3, 2024, 9:00 AM EDT - 10 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

Aug 30, 2024, 9:00 AM EDT - 10 months ago

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

Aug 29, 2024, 9:00 AM EDT - 10 months ago

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

Aug 21, 2024, 9:00 AM EDT - 11 months ago

Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

Aug 9, 2024, 9:00 AM EDT - 11 months ago

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Jul 24, 2024, 10:52 AM EDT - 1 year ago

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

Jul 3, 2024, 10:51 AM EDT - 1 year ago

Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut

Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital

Jul 2, 2024, 6:24 PM EDT - 1 year ago

Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Jul 2, 2024, 5:15 PM EDT - 1 year ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

Jul 2, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.

Jun 20, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.

Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)

Jun 14, 2024, 1:41 PM EDT - 1 year ago

Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)

Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

Jun 11, 2024, 7:20 PM EDT - 1 year ago

Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®

Jun 11, 2024, 9:00 AM EDT - 1 year ago

Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®

Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

Jun 10, 2024, 11:49 AM EDT - 1 year ago

Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024

Jun 6, 2024, 2:56 PM EDT - 1 year ago

Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024

Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company

May 30, 2024, 1:19 PM EDT - 1 year ago

Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company

nelly2k
nelly2k Jun. 27 at 4:17 AM
$SRNE $SCLX who is still holding SRNE .. any longs or shorts still here? or we all retired and living on the beach.
0 · Reply
Tight_grapes
Tight_grapes Jun. 27 at 3:58 AM
$SCLX $SRNE Can a bull explain how this company can remain solvent? This could file for BK any day at this point. Exiting 2025 intact seems close to impossible barring some sort of major asset sale or miraculous rabbit puled out of hat w/ the FDA. They have no trajectory to make money, or even close that I can see, they cannot dilute much more, and the SPAC has not consummated in close to 12 months after annoucement... This looks very much like Sorrento 2.0 and no matter how much Ji "wants" to help, a failing company is a failing company which try as he might, is still failing... Anyone?
1 · Reply
JustAGoodOleBoy22
JustAGoodOleBoy22 Jun. 27 at 3:50 AM
$SCLX Question...hypothetically if Hji and Shah went on shark tank...could they convince anyone to invest in this shit
0 · Reply
JustAGoodOleBoy22
JustAGoodOleBoy22 Jun. 27 at 3:46 AM
$SCLX $37 million Market Cap....how much does the BOD and Ceo make again?
0 · Reply
JustAGoodOleBoy22
JustAGoodOleBoy22 Jun. 27 at 12:10 AM
$SCLX So Hji Jr...the former tennis star...Mba at Woke ColumbiaU (paid for by us) ...works for Moelis...? huh
0 · Reply
Rookie69
Rookie69 Jun. 26 at 7:18 PM
$SCLX Shareholders can only pray that this next phase 3 is kicked back by the FDA too. How awesome would it be to run more trials and gather even that much more efficacy dats
1 · Reply
SCLXSUX
SCLXSUX Jun. 26 at 6:07 PM
$SCLX - Ji set the price target!!!! I think he's probably close on his projection. It should bring in the remaining gullible looking for the "easy money". You might as well build a fire with your money and roast some weenies, because you won't have any money left after you invest in this steaming pile of...
1 · Reply
qlox
qlox Jun. 26 at 5:39 PM
$SCLX A price target of $367.50 ??? Are you out of your freaking mind!?
1 · Reply
Tight_grapes
Tight_grapes Jun. 26 at 4:55 PM
$SCLX $SRNE I would bet that the professionals Ji hired at Lantham, M3, and Moelis were not aware at the bankruptcy filing that Scilex was worthless...that the ZTlido patent was junk, Semdexa failed in its Phase 3 design, etc. That truth likely was uncovered during the tortuous BK process and the entire bankruptcy went FUBAR as a result... Lol. But the pumpers attacked the professionals and the courts...not Ji. Ji screwing up is the ESSENCE, the DNA, the foundation of ALL his business dealings. How he can do so, and do so HUGELY, while self-enriching is nothing short of phenomenal. He is the Stephen Curry enrichment by failure. A true legend.
1 · Reply
Jigoingtoprison
Jigoingtoprison Jun. 26 at 4:38 PM
$SCLX this will follow suit with #srne … I’ve been involved in JI company’s for 7 years. Biggest mistake of my life.
1 · Reply
Bat_shtt_crazy
Bat_shtt_crazy Jun. 26 at 4:37 PM
$SCLX Half way through the day and only 14,000 shares traded. Has someone finally been handcuffed for abusive naked shorting?
1 · Reply
Bat_shtt_crazy
Bat_shtt_crazy Jun. 26 at 2:35 PM
$SRNE $SCLX
0 · Reply
Knowledgeworthmore
Knowledgeworthmore Jun. 26 at 1:59 PM
$VG $SCLX heads up.
0 · Reply
JustAGoodOleBoy22
JustAGoodOleBoy22 Jun. 26 at 1:26 PM
$SCLX This guy/gal and his her BLACK cloud forecast is the biggest critic of everything requiring any and every investor w long position to present absolute proof and 100% guarantees for every angle of any risk all while he she demands the upmost courtesy and respect for his/her delicate emotional well being.....while spewing his her disrespect at will.... Don't mind me "just calling out the obvious" here MAGA!!!!! GLTA
0 · Reply
Awaywithshorts
Awaywithshorts Jun. 26 at 10:51 AM
$SCLX Confident
0 · Reply
Tight_grapes
Tight_grapes Jun. 25 at 11:18 PM
$SCLX $SRNE Leading up the calamitous Sorrento bankruptcy, it's too bad social media did not have the brains and courage to call out the obvious massive risk. I'll leave this here - if Scilex files for bankruptcy not a single person online can ever say they were surprised or misled. - They lose money every quarter - Their lead product appears to have lost patent protection, and this could impact their 2nd lead candidate SP-103 for neck/low back - Their lead candidate requires a Phase 3 trial that shows no sign of starting in clinicaltrials.gov or spend in any of their 10Q/K's - Their expenses are ridiculous and the executive compensation absurd - The voting structure is horrible, and management incentive are easily perverted for self-enrichment & self-preservation - The investor base is too broke and/or too stupid to hold management accountable legally - They present no plan, communicate no strategy, and treat investors as potential litigants or adversaries Spelling out the obvious
1 · Reply
Skunky
Skunky Jun. 25 at 10:31 PM
$SCLX The additional trial request is about labeling and durability of effect, not failure.
3 · Reply
Tight_grapes
Tight_grapes Jun. 25 at 7:33 PM
$SCLX $SRNE So this is modus operandi of a pumper...trumpet a failure as a success...Sorrento covered up this failure, and it sunk not only Sorrento, but Scilex... Why do you think in BK no one wanted Scilex? Semdexa needed ANOTHER trial AFTER a claimed "pivotal" success...the hope is the "new" FDA waives that but I doubt it. Or they have secretly funded trials, doubt that too... This poster is a VERY bad actor, as are more pumpers on Band of brothers. Call them out, but if you do on Band of Brothers they'll ban you...
1 · Reply
Skunky
Skunky Jun. 25 at 7:25 PM
$SCLX Botched? You mean the randomized, double-blind, placebo-controlled Phase 3 trial that met its primary endpoint with a p-value of 0.019? That’s not botched, that’s clinically significant. Sorry if facts don't fit your short thesis.
1 · Reply
Tight_grapes
Tight_grapes Jun. 25 at 6:17 PM
$SCLX $SRNE Has anyone noticed there is zero financial due diligence going on with pumper. Just social media posts, political posts, conspiracies, etc. Nothing product related. Nothing financial related. Nothing management related. 98% don't know any better and should never have invested in a single stock outside an ETF. 2% know better and are serious con artists...
2 · Reply
BBatteries
BBatteries Jun. 25 at 3:38 PM
$SCLX Setting up to test $7.52
1 · Reply
Reallybigbags
Reallybigbags Jun. 25 at 3:11 PM
$SCLX stock is .15 cents pre split and these guys still pumping dreams. Soooooo many other stocks have been moving like crazy. MOVE ON
1 · Reply